 Yuki Fujiwara
Concepts (368)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages | 33 | 2026 | 1507 | 2.880 |
Why?
| | Sialic Acid Binding Ig-like Lectin 1 | 6 | 2026 | 11 | 2.080 |
Why?
| | B7-H1 Antigen | 15 | 2026 | 244 | 1.910 |
Why?
| | Tumor Microenvironment | 19 | 2026 | 734 | 1.570 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 6 | 2025 | 66 | 1.480 |
Why?
| | Macrophage Activation | 9 | 2025 | 181 | 1.350 |
Why?
| | Receptors, Cell Surface | 6 | 2025 | 372 | 1.280 |
Why?
| | Antigens, CD | 7 | 2025 | 558 | 1.220 |
Why?
| | Neoplasms | 9 | 2026 | 2906 | 0.970 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2024 | 231 | 0.930 |
Why?
| | Immunotherapy | 11 | 2026 | 666 | 0.900 |
Why?
| | Immunity | 3 | 2021 | 140 | 0.830 |
Why?
| | Lymph Nodes | 7 | 2026 | 503 | 0.820 |
Why?
| | Hepatoblastoma | 4 | 2025 | 52 | 0.780 |
Why?
| | Mice | 46 | 2026 | 18329 | 0.780 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 6 | 2026 | 153 | 0.750 |
Why?
| | Liver Neoplasms | 6 | 2025 | 776 | 0.740 |
Why?
| | Cell Line, Tumor | 22 | 2025 | 3542 | 0.730 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 2214 | 0.680 |
Why?
| | Carcinoma, Renal Cell | 5 | 2025 | 230 | 0.660 |
Why?
| | Animals | 52 | 2026 | 38030 | 0.640 |
Why?
| | Hyaluronan Receptors | 2 | 2018 | 104 | 0.630 |
Why?
| | Lung Neoplasms | 9 | 2026 | 2664 | 0.630 |
Why?
| | Colorectal Neoplasms | 6 | 2026 | 866 | 0.620 |
Why?
| | Atherosclerosis | 4 | 2024 | 409 | 0.610 |
Why?
| | Immunologic Factors | 2 | 2018 | 260 | 0.590 |
Why?
| | Flavanones | 2 | 2022 | 6 | 0.580 |
Why?
| | Kidney Neoplasms | 5 | 2025 | 413 | 0.580 |
Why?
| | Chemokine CXCL10 | 3 | 2024 | 39 | 0.570 |
Why?
| | Thalidomide | 1 | 2018 | 43 | 0.550 |
Why?
| | Orosomucoid | 3 | 2025 | 9 | 0.550 |
Why?
| | Diosgenin | 1 | 2018 | 2 | 0.540 |
Why?
| | Saponins | 1 | 2018 | 12 | 0.540 |
Why?
| | Immunomodulation | 1 | 2018 | 99 | 0.530 |
Why?
| | Plant Extracts | 2 | 2025 | 188 | 0.510 |
Why?
| | Cell Proliferation | 13 | 2025 | 2507 | 0.510 |
Why?
| | Colonic Neoplasms | 4 | 2024 | 257 | 0.500 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 156 | 0.490 |
Why?
| | Breast Neoplasms | 4 | 2023 | 2382 | 0.470 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 2 | 2026 | 12 | 0.460 |
Why?
| | Programmed Cell Death 1 Receptor | 5 | 2025 | 265 | 0.460 |
Why?
| | Biomarkers, Tumor | 9 | 2026 | 1321 | 0.460 |
Why?
| | Anti-Inflammatory Agents | 3 | 2026 | 477 | 0.450 |
Why?
| | Acetylcysteine | 2 | 2026 | 139 | 0.440 |
Why?
| | Sulfides | 2 | 2026 | 92 | 0.440 |
Why?
| | Foam Cells | 4 | 2022 | 17 | 0.420 |
Why?
| | Mice, Inbred C57BL | 17 | 2026 | 5983 | 0.410 |
Why?
| | Glycation End Products, Advanced | 3 | 2020 | 81 | 0.410 |
Why?
| | Cell Communication | 6 | 2023 | 328 | 0.400 |
Why?
| | Cholangiocarcinoma | 2 | 2025 | 108 | 0.390 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1996 | 0.380 |
Why?
| | Bile Duct Neoplasms | 2 | 2025 | 131 | 0.380 |
Why?
| | Neuroendocrine Tumors | 2 | 2025 | 119 | 0.360 |
Why?
| | Tomatine | 1 | 2012 | 1 | 0.360 |
Why?
| | Membrane Glycoproteins | 2 | 2025 | 499 | 0.360 |
Why?
| | Sterol O-Acyltransferase | 1 | 2012 | 6 | 0.360 |
Why?
| | Hyperlipidemias | 2 | 2014 | 120 | 0.360 |
Why?
| | Liver | 4 | 2026 | 1896 | 0.360 |
Why?
| | Humans | 63 | 2026 | 145474 | 0.360 |
Why?
| | Apolipoproteins E | 1 | 2012 | 93 | 0.350 |
Why?
| | Macrophages, Peritoneal | 2 | 2024 | 89 | 0.340 |
Why?
| | Pancreatic Neoplasms | 3 | 2025 | 928 | 0.340 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 61 | 0.330 |
Why?
| | Down-Regulation | 2 | 2017 | 618 | 0.330 |
Why?
| | T-Lymphocyte Subsets | 2 | 2026 | 418 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2024 | 1443 | 0.310 |
Why?
| | Mice, Knockout | 8 | 2026 | 3124 | 0.310 |
Why?
| | STAT3 Transcription Factor | 5 | 2023 | 206 | 0.310 |
Why?
| | Aorta | 3 | 2024 | 440 | 0.300 |
Why?
| | Melanoma, Experimental | 2 | 2022 | 109 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2024 | 641 | 0.300 |
Why?
| | Thiophenes | 3 | 2023 | 117 | 0.300 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 1189 | 0.280 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2023 | 122 | 0.280 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 2 | 2025 | 14 | 0.280 |
Why?
| | Ligands | 4 | 2025 | 665 | 0.270 |
Why?
| | Interferon-alpha | 3 | 2025 | 193 | 0.260 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2025 | 1140 | 0.250 |
Why?
| | Disease Models, Animal | 10 | 2026 | 4560 | 0.250 |
Why?
| | Neoplastic Syndromes, Hereditary | 2 | 2024 | 47 | 0.240 |
Why?
| | Immunohistochemistry | 3 | 2025 | 1716 | 0.240 |
Why?
| | Brain Neoplasms | 3 | 2025 | 1329 | 0.240 |
Why?
| | Nephritis, Hereditary | 1 | 2026 | 3 | 0.240 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2026 | 8 | 0.240 |
Why?
| | Monocytes | 3 | 2025 | 539 | 0.240 |
Why?
| | Antigens, CD7 | 1 | 2025 | 2 | 0.240 |
Why?
| | Mycobacterium avium | 1 | 2026 | 21 | 0.240 |
Why?
| | Signal Transduction | 11 | 2025 | 5216 | 0.230 |
Why?
| | Apyrase | 1 | 2025 | 27 | 0.230 |
Why?
| | Thyroid Nuclear Factor 1 | 1 | 2025 | 16 | 0.230 |
Why?
| | Mice, Inbred BALB C | 3 | 2025 | 1261 | 0.230 |
Why?
| | Interleukin-6 | 4 | 2026 | 776 | 0.230 |
Why?
| | Proteinuria | 1 | 2026 | 104 | 0.230 |
Why?
| | Prognosis | 9 | 2026 | 4316 | 0.230 |
Why?
| | Interleukins | 2 | 2025 | 248 | 0.220 |
Why?
| | Immune Evasion | 1 | 2026 | 61 | 0.220 |
Why?
| | Chondrosarcoma | 1 | 2025 | 17 | 0.220 |
Why?
| | HTLV-I Infections | 1 | 2025 | 29 | 0.220 |
Why?
| | Orthomyxoviridae Infections | 1 | 2026 | 71 | 0.220 |
Why?
| | Kidney Glomerulus | 1 | 2026 | 125 | 0.220 |
Why?
| | Carcinoma, Papillary | 1 | 2025 | 77 | 0.220 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 72 | 0.220 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2025 | 76 | 0.220 |
Why?
| | Neoadjuvant Therapy | 2 | 2025 | 465 | 0.210 |
Why?
| | Female | 28 | 2026 | 78844 | 0.210 |
Why?
| | Interleukin-10 | 3 | 2021 | 309 | 0.210 |
Why?
| | Macrophage Colony-Stimulating Factor | 2 | 2022 | 20 | 0.210 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2026 | 138 | 0.210 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2026 | 202 | 0.210 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 161 | 0.210 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2026 | 364 | 0.210 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2024 | 22 | 0.210 |
Why?
| | Diet, High-Fat | 1 | 2025 | 266 | 0.200 |
Why?
| | Carcinoma, Embryonal | 1 | 2023 | 3 | 0.200 |
Why?
| | Photochemotherapy | 1 | 2024 | 39 | 0.200 |
Why?
| | Clodronic Acid | 1 | 2023 | 19 | 0.200 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 192 | 0.190 |
Why?
| | Aortic Diseases | 1 | 2024 | 125 | 0.190 |
Why?
| | Acetaminophen | 1 | 2026 | 267 | 0.190 |
Why?
| | Neovascularization, Pathologic | 1 | 2025 | 286 | 0.190 |
Why?
| | Male | 29 | 2026 | 72842 | 0.190 |
Why?
| | Nutritional Status | 1 | 2026 | 353 | 0.190 |
Why?
| | Phenotype | 4 | 2025 | 3155 | 0.190 |
Why?
| | beta-Cyclodextrins | 1 | 2023 | 32 | 0.190 |
Why?
| | Up-Regulation | 1 | 2026 | 847 | 0.190 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2023 | 71 | 0.190 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2025 | 881 | 0.190 |
Why?
| | Bone Neoplasms | 1 | 2025 | 259 | 0.180 |
Why?
| | Chemokine CXCL13 | 1 | 2022 | 15 | 0.180 |
Why?
| | Endoplasmic Reticulum Stress | 2 | 2020 | 118 | 0.180 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 76 | 0.180 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2022 | 12 | 0.180 |
Why?
| | Testicular Neoplasms | 1 | 2023 | 111 | 0.180 |
Why?
| | Melanoma | 2 | 2022 | 759 | 0.180 |
Why?
| | Cisplatin | 1 | 2024 | 345 | 0.180 |
Why?
| | Immune System Diseases | 1 | 2022 | 37 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1217 | 0.180 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 17 | 0.180 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 38 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2025 | 293 | 0.180 |
Why?
| | Sulfur Compounds | 1 | 2021 | 7 | 0.180 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2021 | 16 | 0.170 |
Why?
| | Osteopontin | 1 | 2021 | 35 | 0.170 |
Why?
| | Cell Line | 5 | 2024 | 2823 | 0.170 |
Why?
| | Sulfoxides | 2 | 2023 | 4 | 0.170 |
Why?
| | Interleukin-12 | 2 | 2022 | 115 | 0.170 |
Why?
| | CD47 Antigen | 1 | 2021 | 42 | 0.170 |
Why?
| | Neuropeptides | 1 | 2021 | 75 | 0.170 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2022 | 117 | 0.170 |
Why?
| | Glioblastoma | 1 | 2025 | 353 | 0.170 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2026 | 339 | 0.170 |
Why?
| | Adipose Tissue | 1 | 2025 | 645 | 0.170 |
Why?
| | Disease Progression | 7 | 2026 | 2864 | 0.170 |
Why?
| | Mouth Neoplasms | 1 | 2022 | 90 | 0.170 |
Why?
| | Immunotherapy, Adoptive | 1 | 2025 | 342 | 0.170 |
Why?
| | Phagocytes | 1 | 2021 | 80 | 0.170 |
Why?
| | Interleukin-1beta | 2 | 2026 | 389 | 0.160 |
Why?
| | Burns, Electric | 1 | 2020 | 25 | 0.160 |
Why?
| | Pneumonia, Viral | 1 | 2026 | 389 | 0.160 |
Why?
| | Penicillium | 1 | 2020 | 8 | 0.160 |
Why?
| | Immune Tolerance | 1 | 2023 | 385 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2021 | 81 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2024 | 534 | 0.160 |
Why?
| | Protective Agents | 1 | 2020 | 42 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2024 | 372 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 170 | 0.150 |
Why?
| | Osteoblasts | 1 | 2020 | 145 | 0.150 |
Why?
| | Cell Movement | 3 | 2022 | 959 | 0.150 |
Why?
| | Oxadiazoles | 1 | 2019 | 37 | 0.140 |
Why?
| | Aged, 80 and over | 7 | 2026 | 8333 | 0.140 |
Why?
| | HEK293 Cells | 1 | 2021 | 741 | 0.140 |
Why?
| | Cytokines | 6 | 2026 | 2067 | 0.140 |
Why?
| | Collagen Type I | 1 | 2019 | 143 | 0.140 |
Why?
| | Kupffer Cells | 1 | 2018 | 52 | 0.140 |
Why?
| | Hepatitis | 1 | 2018 | 43 | 0.140 |
Why?
| | Aged | 12 | 2026 | 26153 | 0.140 |
Why?
| | Neoplasm Metastasis | 1 | 2021 | 688 | 0.140 |
Why?
| | Cholesterol Esters | 2 | 2022 | 7 | 0.140 |
Why?
| | Aortitis | 1 | 2018 | 10 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2021 | 1164 | 0.140 |
Why?
| | Arginine | 1 | 2019 | 264 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 224 | 0.130 |
Why?
| | Aging | 3 | 2025 | 1969 | 0.130 |
Why?
| | Transcriptome | 1 | 2024 | 1038 | 0.130 |
Why?
| | Single-Chain Antibodies | 1 | 2017 | 13 | 0.130 |
Why?
| | Neoplasm Transplantation | 3 | 2024 | 246 | 0.130 |
Why?
| | Interferon Type I | 1 | 2018 | 147 | 0.130 |
Why?
| | Pyridinium Compounds | 1 | 2017 | 31 | 0.130 |
Why?
| | Middle Aged | 13 | 2026 | 36215 | 0.130 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2023 | 177 | 0.130 |
Why?
| | Lysine | 1 | 2019 | 305 | 0.130 |
Why?
| | Mutation | 2 | 2025 | 4075 | 0.130 |
Why?
| | Cells, Cultured | 6 | 2024 | 4148 | 0.120 |
Why?
| | Skin Neoplasms | 2 | 2022 | 849 | 0.120 |
Why?
| | Mice, Inbred ICR | 3 | 2026 | 113 | 0.120 |
Why?
| | Lycopodium | 1 | 2016 | 1 | 0.120 |
Why?
| | Lung | 3 | 2026 | 4106 | 0.120 |
Why?
| | Apoptosis | 3 | 2020 | 2440 | 0.120 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2016 | 23 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 664 | 0.120 |
Why?
| | Kidney Diseases | 1 | 2020 | 425 | 0.120 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 561 | 0.120 |
Why?
| | Levofloxacin | 1 | 2015 | 21 | 0.110 |
Why?
| | Sarcoma | 1 | 2018 | 207 | 0.110 |
Why?
| | Lymphoma | 1 | 2017 | 237 | 0.110 |
Why?
| | Free Radical Scavengers | 1 | 2015 | 82 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 2 | 2021 | 276 | 0.110 |
Why?
| | Scavenger Receptors, Class A | 2 | 2011 | 12 | 0.110 |
Why?
| | Quinolines | 1 | 2016 | 190 | 0.110 |
Why?
| | Helicobacter Infections | 1 | 2014 | 30 | 0.100 |
Why?
| | Helicobacter pylori | 1 | 2014 | 44 | 0.100 |
Why?
| | Coculture Techniques | 3 | 2021 | 247 | 0.100 |
Why?
| | Serpins | 2 | 2024 | 28 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2020 | 925 | 0.100 |
Why?
| | Survival Rate | 3 | 2025 | 2090 | 0.090 |
Why?
| | Mice, Knockout, ApoE | 2 | 2024 | 11 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2015 | 305 | 0.090 |
Why?
| | Hydrogels | 1 | 2019 | 701 | 0.090 |
Why?
| | Cricetinae | 1 | 2012 | 305 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1767 | 0.090 |
Why?
| | Mannose | 2 | 2023 | 23 | 0.080 |
Why?
| | Antibodies | 2 | 2023 | 397 | 0.080 |
Why?
| | Influenza A virus | 2 | 2026 | 119 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 595 | 0.080 |
Why?
| | Lymphocyte Activation | 2 | 2025 | 1132 | 0.080 |
Why?
| | Neutrophils | 3 | 2026 | 1124 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2023 | 635 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2015 | 919 | 0.070 |
Why?
| | Influenza, Human | 1 | 2015 | 624 | 0.070 |
Why?
| | Survival Analysis | 2 | 2022 | 1374 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2024 | 611 | 0.070 |
Why?
| | Inflammation | 4 | 2026 | 2878 | 0.060 |
Why?
| | Structure-Activity Relationship | 2 | 2020 | 563 | 0.060 |
Why?
| | Molecular Structure | 2 | 2020 | 486 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2026 | 17291 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2025 | 2188 | 0.060 |
Why?
| | Hep G2 Cells | 1 | 2026 | 73 | 0.060 |
Why?
| | Collagen Type IV | 1 | 2026 | 27 | 0.060 |
Why?
| | Protective Factors | 1 | 2026 | 99 | 0.060 |
Why?
| | Sirtuin 1 | 1 | 2025 | 34 | 0.060 |
Why?
| | Nutrition Assessment | 1 | 2026 | 90 | 0.060 |
Why?
| | Inducible T-Cell Co-Stimulator Ligand | 1 | 2025 | 4 | 0.060 |
Why?
| | Cell Dedifferentiation | 1 | 2025 | 32 | 0.060 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2025 | 32 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2021 | 784 | 0.050 |
Why?
| | Podocytes | 1 | 2026 | 80 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2026 | 207 | 0.050 |
Why?
| | PPAR gamma | 1 | 2025 | 178 | 0.050 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2026 | 166 | 0.050 |
Why?
| | Inflammasomes | 1 | 2026 | 144 | 0.050 |
Why?
| | Fibroblast Growth Factors | 1 | 2025 | 188 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1923 | 0.050 |
Why?
| | Bevacizumab | 1 | 2025 | 168 | 0.050 |
Why?
| | Mesentery | 1 | 2024 | 44 | 0.050 |
Why?
| | Glutathione | 1 | 2026 | 370 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2025 | 506 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2028 | 0.050 |
Why?
| | Adiponectin | 1 | 2025 | 241 | 0.050 |
Why?
| | Lymphocytes | 1 | 2026 | 376 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2025 | 331 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2024 | 63 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2025 | 238 | 0.050 |
Why?
| | Cytoplasm | 1 | 2024 | 254 | 0.050 |
Why?
| | Viral Load | 1 | 2026 | 526 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2025 | 160 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2024 | 298 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2024 | 762 | 0.050 |
Why?
| | Denervation | 1 | 2022 | 27 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 53 | 0.050 |
Why?
| | Pancreatectomy | 1 | 2025 | 289 | 0.050 |
Why?
| | Lipocalin-2 | 1 | 2022 | 80 | 0.050 |
Why?
| | Scavenger Receptors, Class B | 1 | 2022 | 14 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2024 | 231 | 0.050 |
Why?
| | Atrophy | 1 | 2022 | 199 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 934 | 0.040 |
Why?
| | Administration, Oral | 1 | 2024 | 866 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 112 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 409 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 2187 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2021 | 133 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 2021 | 254 | 0.040 |
Why?
| | Blotting, Western | 1 | 2023 | 1179 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2024 | 431 | 0.040 |
Why?
| | Arginase | 1 | 2020 | 26 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2023 | 382 | 0.040 |
Why?
| | Mice, Nude | 1 | 2022 | 679 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 289 | 0.040 |
Why?
| | Tumor Burden | 1 | 2022 | 325 | 0.040 |
Why?
| | Adult | 5 | 2025 | 40777 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2021 | 147 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2021 | 208 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2020 | 156 | 0.040 |
Why?
| | Hepatocytes | 1 | 2021 | 224 | 0.040 |
Why?
| | NF-kappa B | 2 | 2016 | 666 | 0.040 |
Why?
| | Cholesterol | 1 | 2022 | 408 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 191 | 0.040 |
Why?
| | Endoribonucleases | 1 | 2020 | 77 | 0.040 |
Why?
| | Phagocytosis | 1 | 2021 | 296 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2025 | 870 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 228 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2022 | 340 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 137 | 0.040 |
Why?
| | Glycosylation | 1 | 2019 | 173 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 423 | 0.040 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2020 | 189 | 0.040 |
Why?
| | RAW 264.7 Cells | 1 | 2018 | 48 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 382 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 296 | 0.030 |
Why?
| | Fibrin | 1 | 2019 | 84 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2018 | 64 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1505 | 0.030 |
Why?
| | Serum Albumin | 1 | 2018 | 147 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 552 | 0.030 |
Why?
| | Doxorubicin | 1 | 2020 | 401 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2023 | 2524 | 0.030 |
Why?
| | Tyrphostins | 1 | 2017 | 18 | 0.030 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2018 | 253 | 0.030 |
Why?
| | Peptide Library | 1 | 2017 | 91 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1266 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2018 | 310 | 0.030 |
Why?
| | Protein Stability | 1 | 2017 | 176 | 0.030 |
Why?
| | Necrosis | 1 | 2018 | 244 | 0.030 |
Why?
| | Chemokine CCL4 | 1 | 2017 | 31 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 48 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3342 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 204 | 0.030 |
Why?
| | Caspase 3 | 1 | 2017 | 242 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5423 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 311 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2238 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 969 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 457 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1509 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 559 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2015 | 164 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1368 | 0.030 |
Why?
| | Fluoroquinolones | 1 | 2015 | 44 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 874 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 506 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2020 | 485 | 0.030 |
Why?
| | Cell Differentiation | 2 | 2014 | 2046 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2015 | 196 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5584 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2014 | 53 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2129 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2021 | 3623 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 203 | 0.020 |
Why?
| | RNA, Bacterial | 1 | 2014 | 182 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2014 | 320 | 0.020 |
Why?
| | Pyridines | 1 | 2017 | 609 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1789 | 0.020 |
Why?
| | Obesity | 1 | 2025 | 3116 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2015 | 499 | 0.020 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2011 | 16 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4295 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2011 | 190 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2947 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11853 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 892 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11772 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2597 | 0.020 |
Why?
| | Shock, Septic | 1 | 2011 | 227 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2015 | 1356 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 588 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 858 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 3204 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1327 | 0.020 |
Why?
| | Child | 1 | 2025 | 22707 | 0.010 |
Why?
|
|
Fujiwara's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|